Literature DB >> 28215899

18F-Fluorodeoxyglucose Positron Emission Tomography Cortical Metabolic Activity Associated with Distinct Agitation Behaviors in Alzheimer Disease.

Gali H Weissberger1, Rebecca J Melrose2, Theresa A Narvaez3, Dylan Harwood4, Mark A Mandelkern5, David L Sultzer4.   

Abstract

OBJECTIVE: This study aimed to investigate the neurobiologic correlates of two distinct clusters of agitation symptoms to identify the unique biologic substrates underlying agitated behaviors.
METHODS: Eighty-eight outpatients with mild to moderate Alzheimer disease (AD) were recruited from the VA Greater Los Angeles Healthcare System Geropsychiatry Outpatient Program. A cross-sectional investigation was conducted of the relationship between cerebral glucose metabolism measured via 18F-fluorodeoxyglucose positron emission tomography and agitated symptoms from the Neuropsychiatric Inventory (NPI) in patients with AD. Two empirically derived clusters of agitation symptoms were investigated: an Agitation factor comprising agitation/aggression and irritability/lability items of the NPI, and a Behavioral Dyscontrol factor comprising elation/euphoria, disinhibition, aberrant motor behavior, sleep, and appetite items of the NPI. Mean cerebral metabolism for patients who scored positively on each of the two factors was compared with mean cerebral metabolism for those who did not.
RESULTS: Patients with AD who scored positively on the Agitation factor showed reduced glucose metabolism of the right temporal, right frontal, and bilateral cingulate cortex. In contrast, the Behavioral Dyscontrol factor did not show specific neurobiologic correlates.
CONCLUSION: Symptoms encompassed within the Agitation factor have distinct neurobiologic underpinnings. The precipitants, course, and outcomes related to these symptoms may be unique from other neuropsychiatric symptoms characteristic of AD. Special attention to treatment of agitated behaviors involving anger, aggressiveness, hostility, and irritability/emotional lability is warranted, because they appear to reflect a clinically relevant symptom cluster with unique underlying neurobiologic correlates. Published by Elsevier Inc.

Entities:  

Keywords:  Alzheimer disease; FDG-PET; agitation; cerebral metabolism

Mesh:

Substances:

Year:  2017        PMID: 28215899     DOI: 10.1016/j.jagp.2017.01.017

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  10 in total

1.  The impact of vascular burden on behavioural and psychological symptoms in older adults with dementia: the BEVASDE study.

Authors:  Raquel Manso-Calderón; Purificación Cacabelos-Pérez; María D Sevillano-García; María E Herrero-Prieto; Rogelio González-Sarmiento
Journal:  Neurol Sci       Date:  2019-09-07       Impact factor: 3.307

2.  Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study.

Authors:  Myuri Ruthirakuhan; Zahinoor Ismail; Nathan Herrmann; Damien Gallagher; Krista L Lanctôt
Journal:  Alzheimers Dement       Date:  2022-02-01       Impact factor: 16.655

3.  Cerebral Responses to Acupuncture at GV24 and Bilateral GB13 in Rat Models of Alzheimer's Disease.

Authors:  Shaoyang Cui; Mingzhu Xu; Jianting Huang; Qing Mei Wang; Xinsheng Lai; Binbin Nie; Baoci Shan; Xun Luo; John Wong; Chunzhi Tang
Journal:  Behav Neurol       Date:  2018-04-30       Impact factor: 3.342

4.  24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.

Authors:  Myuri Ruthirakuhan; Nathan Herrmann; Ana C Andreazza; Nicolaas Paul L G Verhoeff; Damien Gallagher; Sandra E Black; Alex Kiss; Krista L Lanctôt
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 5.  New approaches to symptomatic treatments for Alzheimer's disease.

Authors:  Jeffrey Cummings
Journal:  Mol Neurodegener       Date:  2021-01-13       Impact factor: 14.195

Review 6.  Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions.

Authors:  Claudia Carrarini; Mirella Russo; Fedele Dono; Filomena Barbone; Marianna G Rispoli; Laura Ferri; Martina Di Pietro; Anna Digiovanni; Paola Ajdinaj; Rino Speranza; Alberto Granzotto; Valerio Frazzini; Astrid Thomas; Andrea Pilotto; Alessandro Padovani; Marco Onofrj; Stefano L Sensi; Laura Bonanni
Journal:  Front Neurol       Date:  2021-04-16       Impact factor: 4.003

7.  Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease.

Authors:  Cécile Tissot; Joseph Therriault; Tharick A Pascoal; Mira Chamoun; Firoza Z Lussier; Melissa Savard; Sulantha S Mathotaarachchi; Andréa L Benedet; Emilie M Thomas; Marlee Parsons; Ziad Nasreddine; Pedro Rosa-Neto; Serge Gauthier
Journal:  Alzheimers Dement (N Y)       Date:  2021-03-31

8.  Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging.

Authors:  Janina Krell-Roesch; Jeremy A Syrjanen; Maria Vassilaki; Val J Lowe; Prashanthi Vemuri; Michelle M Mielke; Mary M Machulda; Gorazd B Stokin; Teresa J Christianson; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Yonas E Geda
Journal:  Am J Geriatr Psychiatry       Date:  2020-06-17       Impact factor: 4.105

Review 9.  Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns.

Authors:  Yaojing Chen; Mingxi Dang; Zhanjun Zhang
Journal:  Mol Neurodegener       Date:  2021-06-07       Impact factor: 14.195

10.  Affective symptoms and regional cerebral tau burden in early-stage Alzheimer's disease.

Authors:  Nicole S Tommasi; Christopher Gonzalez; Danielle Briggs; Michael J Properzi; Jennifer R Gatchel; Gad A Marshall
Journal:  Int J Geriatr Psychiatry       Date:  2021-03-15       Impact factor: 3.850

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.